- In March 2022, MoonLake had started the Phase II trial of nanobody, sonelokimab for treating moderate-to-severe hidradenitis suppurativa (HS). Sonelokimab has the potential to treat inflammatory diseases by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that cause inflammation in the body.
